Interpace Diagnostics® is a leading provider of molecular testing for indeterminate thyroid nodules. Our unique dual-platform test utilizing ThyGeNEXT®, an oncogene mutation panel, and ThyraMIR®, a microRNA risk classifier, empowers patient management by helping to resolve diagnostic uncertainty using our selected Markers That Matter®.
ThyGeNext + ThyraMIR can accurately rule-in or rule-out disease, is fully validated and has very simple FNA specimen storage and handling requirements.